First-line sparsentan use associated with proteinuria reduction in IgA nephropathy
BOSTON — Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to researchers.Researchers presented interim findings from the SPARTAN trial at the National Kidney Foundation Spring Clinical Meetings. SPARTAN is a phase 2, open-label, single-arm, multicenter trial of